TY - JOUR T1 - A once yearly IV infusion of zoledronic acid prevented fractures in postmenopausal women with osteoporosis JF - Evidence Based Medicine JO - Evid Based Med SP - 145 LP - 145 DO - 10.1136/ebm.12.5.145 VL - 12 IS - 5 A2 - , Y1 - 2007/10/01 UR - http://ebm.bmj.com/content/12/5/145.abstract N2 - Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–22.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In postmenopausal women with osteoporosis, does a once yearly intravenous infusion of zoledronic acid reduce the incidence of fractures? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ IM/Ambulatory care ★★★★★★★ Rheumatology ★★★★★★★ Endocrine ★★★★★★☆ Geriatrics ★★★★★★☆ Design: randomised placebo controlled trial (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly [HORIZON]). Allocation: not concealed.* Blinding: blinded (outcome assessors).* Follow-up period: 36 months. Setting: clinics in 25 countries in Europe, North and Latin America, Australia, and Asia. Patients: 7765 postmenopausal women (mean age 73 y) with a bone mineral density T score ⩽2.5 at the femoral neck, with or without vertebral fractures, or with a T score ⩽1.5 and ⩾2 mild or 1 moderate vertebral fractures. Women were grouped as stratum 1 (n = 6113) if they were not taking … ER -